Paper highlight: 'Hi-JAK-ing' cancer by inhibiting Jak2

Sep 13, 2010

Myeloproliferative neoplasms (MPN) comprise a family of blood cancers characterized by clonal expansion of a single blood cell type.

Untreated, these cancers can progress to bone marrow failure and acute myeloid .

Several groups have identified activating mutations in the JAK2 gene as associated with MPN; JAK2 inhibition has therefore emerged as approach to MPN therapy. Thus far, however, JAK2 inhibition strategies have had limited efficacy and have been accompanied by significant toxicity.

In this paper, Ross Levine and his group at the Memorial Sloane Kettering Cancer Center, New York, describe an indirect approach to reducing JAK2 activity by pharmacologically targeting HSP90, a that stabilizes JAK2.

Inhibiting HSP90 normalized blood counts and improved survival in two mouse models of MPN, and the treatment promoted JAK2 degradation in samples from MPN patients.

The authors believe that targeting HSP90, perhaps in combination with JAK2 inhibition, may be the way forward in the treatment of patients with MPN.

Explore further: Death rates from pancreatic cancer predicted to rise in Europe in 2014

More information: HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans: www.jci.org/articles/view/42442?key=7ef55d4a4ce9ffed3af0

Provided by Journal of Clinical Investigation

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Genetic abnormality may increase risk of blood disorders

Mar 15, 2009

Researchers at Memorial Sloan-Kettering Cancer Center (MSKCC) have shown for the first time that a tendency to develop some blood disorders may be inherited. Their research, published online today in Nature Genetics, identi ...

Protein key to control, growth of blood cells

Aug 13, 2008

New research sheds light on the biological events by which stem cells in the bone marrow develop into the broad variety of cells that circulate in the blood. The findings may help improve the success of bone marrow transplants ...

New drug for children with high-risk leukemia

Jul 28, 2009

Each year, approximately 4,500 children in America are diagnosed with leukemia, according to the Leukemia and Lymphoma Society. A potentially deadly cancer of the blood, it is the most common cancer in children.

Recommended for you

User comments : 0

More news stories